“ShangPharma Innovation Inc. (South San Francisco, Calif.) will fund preclinical research at the Icahn School of Medicine at Mount Sinai (New York, N.Y.) to validate drug targets and discover drug candidates. ShangPharma Innovation said the partners will share in profits for resulting therapeutics, but declined to disclose financial terms.
ShangPharma Innovation’s affiliated CRO Shanghai ChemPartner Co. Ltd. (Shanghai, China) will also provide CRO services during the multi-year partnership. Both are affiliated with ShangPharma Corp. (Shanghai, China).
ShangPharma Innovation Inc., South San Francisco, Calif. Icahn School of Medicine at Mount…”
Media Inquiries
Heidi Chokeir, Ph.D.
Canale Communications
[email protected]
619-849-5375